vs
Side-by-side financial comparison of Hologic (HOLX) and LCI INDUSTRIES (LCII). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $932.7M, roughly 1.1× LCI INDUSTRIES). Hologic runs the higher net margin — 17.1% vs 2.0%, a 15.1% gap on every dollar of revenue. On growth, LCI INDUSTRIES posted the faster year-over-year revenue change (16.1% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $64.3M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -1.8%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Lucky Core Industries Limited, formerly known as ICI Pakistan, is a Pakistani conglomerate company headquartered in Karachi. It manufactures polyester, pharmaceutical, agrochemical, soda ash, and veterinary medicine.
HOLX vs LCII — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $932.7M |
| Net Profit | $179.1M | $18.7M |
| Gross Margin | 56.0% | 22.1% |
| Operating Margin | 22.6% | 3.8% |
| Net Margin | 17.1% | 2.0% |
| Revenue YoY | 2.5% | 16.1% |
| Net Profit YoY | -10.9% | 95.7% |
| EPS (diluted) | $0.79 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $932.7M | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $1.0B | $1.0B | ||
| Q4 24 | $1.0B | $803.1M | ||
| Q3 24 | $988.0M | $915.5M | ||
| Q2 24 | $1.0B | $1.1B | ||
| Q1 24 | $1.0B | $968.0M |
| Q4 25 | $179.1M | $18.7M | ||
| Q3 25 | $187.2M | $62.5M | ||
| Q2 25 | $194.9M | $57.6M | ||
| Q1 25 | $-17.4M | $49.4M | ||
| Q4 24 | $201.0M | $9.5M | ||
| Q3 24 | $178.6M | $35.6M | ||
| Q2 24 | $194.5M | $61.2M | ||
| Q1 24 | $169.9M | $36.5M |
| Q4 25 | 56.0% | 22.1% | ||
| Q3 25 | 55.6% | 24.4% | ||
| Q2 25 | 56.3% | 24.4% | ||
| Q1 25 | 37.5% | 24.1% | ||
| Q4 24 | 56.8% | 21.1% | ||
| Q3 24 | 56.4% | 24.0% | ||
| Q2 24 | 55.4% | 25.3% | ||
| Q1 24 | 53.3% | 23.1% |
| Q4 25 | 22.6% | 3.8% | ||
| Q3 25 | 22.6% | 7.3% | ||
| Q2 25 | 24.9% | 7.9% | ||
| Q1 25 | -0.7% | 7.8% | ||
| Q4 24 | 22.5% | 2.0% | ||
| Q3 24 | 23.3% | 5.9% | ||
| Q2 24 | 24.1% | 8.6% | ||
| Q1 24 | 20.7% | 6.0% |
| Q4 25 | 17.1% | 2.0% | ||
| Q3 25 | 17.8% | 6.0% | ||
| Q2 25 | 19.0% | 5.2% | ||
| Q1 25 | -1.7% | 4.7% | ||
| Q4 24 | 19.7% | 1.2% | ||
| Q3 24 | 18.1% | 3.9% | ||
| Q2 24 | 19.2% | 5.8% | ||
| Q1 24 | 16.7% | 3.8% |
| Q4 25 | $0.79 | $0.79 | ||
| Q3 25 | $0.84 | $2.55 | ||
| Q2 25 | $0.86 | $2.29 | ||
| Q1 25 | $-0.08 | $1.94 | ||
| Q4 24 | $0.87 | $0.37 | ||
| Q3 24 | $0.75 | $1.39 | ||
| Q2 24 | $0.82 | $2.40 | ||
| Q1 24 | $0.72 | $1.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $222.6M |
| Total DebtLower is stronger | $2.5B | $945.2M |
| Stockholders' EquityBook value | $5.2B | $1.4B |
| Total Assets | $9.2B | $3.2B |
| Debt / EquityLower = less leverage | 0.48× | 0.69× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $222.6M | ||
| Q3 25 | $2.2B | $199.7M | ||
| Q2 25 | $1.9B | $191.9M | ||
| Q1 25 | $1.6B | $231.2M | ||
| Q4 24 | $2.0B | $165.8M | ||
| Q3 24 | $2.3B | $161.2M | ||
| Q2 24 | $2.4B | $130.4M | ||
| Q1 24 | $2.2B | $22.6M |
| Q4 25 | $2.5B | $945.2M | ||
| Q3 25 | $2.5B | $947.8M | ||
| Q2 25 | $2.5B | $948.0M | ||
| Q1 25 | $2.5B | $938.3M | ||
| Q4 24 | $2.5B | $757.3M | ||
| Q3 24 | $2.5B | $822.5M | ||
| Q2 24 | $2.5B | $829.7M | ||
| Q1 24 | $2.6B | $855.3M |
| Q4 25 | $5.2B | $1.4B | ||
| Q3 25 | $5.0B | $1.4B | ||
| Q2 25 | $4.8B | $1.4B | ||
| Q1 25 | $4.6B | $1.4B | ||
| Q4 24 | $4.8B | $1.4B | ||
| Q3 24 | $5.1B | $1.4B | ||
| Q2 24 | $5.0B | $1.4B | ||
| Q1 24 | $4.8B | $1.4B |
| Q4 25 | $9.2B | $3.2B | ||
| Q3 25 | $9.0B | $3.2B | ||
| Q2 25 | $8.8B | $3.2B | ||
| Q1 25 | $8.5B | $3.1B | ||
| Q4 24 | $8.7B | $2.9B | ||
| Q3 24 | $9.2B | $3.0B | ||
| Q2 24 | $8.9B | $3.0B | ||
| Q1 24 | $8.7B | $3.0B |
| Q4 25 | 0.48× | 0.69× | ||
| Q3 25 | 0.50× | 0.70× | ||
| Q2 25 | 0.52× | 0.68× | ||
| Q1 25 | 0.55× | 0.69× | ||
| Q4 24 | 0.53× | 0.55× | ||
| Q3 24 | 0.49× | 0.58× | ||
| Q2 24 | 0.51× | 0.60× | ||
| Q1 24 | 0.53× | 0.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $78.9M |
| Free Cash FlowOCF − Capex | $215.2M | $64.3M |
| FCF MarginFCF / Revenue | 20.5% | 6.9% |
| Capex IntensityCapex / Revenue | 1.4% | 1.6% |
| Cash ConversionOCF / Net Profit | 1.28× | 4.22× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $278.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $78.9M | ||
| Q3 25 | $355.1M | $97.2M | ||
| Q2 25 | $343.3M | $112.2M | ||
| Q1 25 | $169.4M | $42.7M | ||
| Q4 24 | $189.3M | $106.6M | ||
| Q3 24 | $367.0M | $78.4M | ||
| Q2 24 | $405.8M | $192.9M | ||
| Q1 24 | $292.4M | $-7.7M |
| Q4 25 | $215.2M | $64.3M | ||
| Q3 25 | $341.4M | $80.9M | ||
| Q2 25 | $330.5M | $99.5M | ||
| Q1 25 | $153.9M | $33.7M | ||
| Q4 24 | $172.5M | $95.7M | ||
| Q3 24 | $350.6M | $68.3M | ||
| Q2 24 | $385.3M | $180.2M | ||
| Q1 24 | $279.6M | $-16.3M |
| Q4 25 | 20.5% | 6.9% | ||
| Q3 25 | 32.5% | 7.8% | ||
| Q2 25 | 32.3% | 9.0% | ||
| Q1 25 | 15.3% | 3.2% | ||
| Q4 24 | 16.9% | 11.9% | ||
| Q3 24 | 35.5% | 7.5% | ||
| Q2 24 | 38.1% | 17.1% | ||
| Q1 24 | 27.5% | -1.7% |
| Q4 25 | 1.4% | 1.6% | ||
| Q3 25 | 1.3% | 1.6% | ||
| Q2 25 | 1.3% | 1.2% | ||
| Q1 25 | 1.5% | 0.9% | ||
| Q4 24 | 1.6% | 1.4% | ||
| Q3 24 | 1.7% | 1.1% | ||
| Q2 24 | 2.0% | 1.2% | ||
| Q1 24 | 1.3% | 0.9% |
| Q4 25 | 1.28× | 4.22× | ||
| Q3 25 | 1.90× | 1.55× | ||
| Q2 25 | 1.76× | 1.95× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | 0.94× | 11.17× | ||
| Q3 24 | 2.05× | 2.20× | ||
| Q2 24 | 2.09× | 3.15× | ||
| Q1 24 | 1.72× | -0.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
LCII
| Travel Trailer And Fifth Wheels | $378.4M | 41% |
| Chassis Chassis Partsand Slideout Mechanisms | $206.1M | 22% |
| Furnitureand Mattresses | $120.4M | 13% |
| Appliances | $69.9M | 7% |
| Other Products | $69.1M | 7% |
| Axlesand Suspension Solutions | $62.3M | 7% |
| Motorhomes | $34.2M | 4% |
